Boston Scientific Corporation $BSX Shares Bought by Gradient Investments LLC

Gradient Investments LLC lifted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 82.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 468,335 shares of the medical equipment provider’s stock after acquiring an additional 211,067 shares during the period. Gradient Investments LLC’s holdings in Boston Scientific were worth $19,989,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of BSX. Brighton Jones LLC increased its stake in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares during the period. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth approximately $26,000. Main Street Financial Solutions LLC grew its holdings in Boston Scientific by 35.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after buying an additional 1,971 shares in the last quarter. Ieq Capital LLC grew its holdings in Boston Scientific by 97.0% in the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after buying an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC increased its position in Boston Scientific by 56.2% in the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after acquiring an additional 2,556 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX opened at $49.35 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 1.22. The firm’s 50 day moving average is $45.75 and its 200-day moving average is $60.73. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50. The stock has a market capitalization of $71.53 billion, a P/E ratio of 19.98, a P/E/G ratio of 1.08 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its board has approved a share repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In related news, Director David C. Habiger bought 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were bought at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the transaction, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Cheryl Pegus bought 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were bought at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the acquisition, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 204,322 shares of company stock worth $9,939,221 over the last quarter. 0.34% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on BSX. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $60.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Piper Sandler reissued an “overweight” rating and set a $65.00 price target on shares of Boston Scientific in a report on Friday, June 12th. Barclays cut their price objective on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research note on Thursday, May 28th. Weiss Ratings downgraded shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, July 7th. Finally, UBS Group lowered their target price on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.